MapLight Therapeutics, Inc. MPLT Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense by Business | ||||||
| All Other Segments | $933K-15.7% | $1.11M-5.3% | $1.17M-44.4% | $2.1M+176% | $761K-66.0% | |
| Chemistry Manufacturing And Controls Expenses | $6.42M— | —— | —— | —— | $3.96M+37.9% | |
| Clinical Trial | $24.82M+5.2% | $23.59M+98.0% | $11.92M-25.6% | $16.02M+726% | $1.94M-60.0% | |
| Employee Related | $15.99M-46.7% | $30.01M+326% | $7.04M+1.2% | $6.96M-1.3% | $7.05M+17.0% | |
| Preclinical Program | $5.52M+63.4% | $3.38M+21.0% | $2.79M— | —— | $6.08M+26.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does MapLight Therapeutics, Inc. break its business down?
- MapLight Therapeutics, Inc. (MPLT) reports research and development expense by business across 5 parts — All Other Segments, Chemistry Manufacturing And Controls Expenses, Clinical Trial, Employee Related and Preclinical Program. Each is extracted from the segment footnotes and tracked over time.
- Where does MapLight Therapeutics, Inc. 's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in MapLight Therapeutics, Inc. 's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.